Share

CRISPR Therapeutics AG (CRSP.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Buy

5-Year Return Est.

+45.0%

CRSP.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

The central tension is that investors are paying roughly $3.1B above net cash for data that does not yet exist, while the only revenue-generating asset delivers just 40 cents on the dollar to this shareholder. Over five years, the evidence chain most likely resolves in the middle: Casgevy compounds into a $500M-800M gross franchise, turning CRSP's collaboration line from drag to modest contribution, while one of the four wholly-owned pillars — most plausibly ANGPTL3 — reaches registrational stage without yet generating revenue. Dilution from the convertible and a probable 2029-2030 raise absorbs part of the gain. The equity appreciates, but through repeated violent repricings rather than a smooth compounding curve.

Net cash near $24 per share anchors roughly 43% of today's price in liquid securities.
Remaining $32 per share is option premium on four wholly-owned programs plus the stake.
Implied 2031 value near $82 requires the in vivo pillar surviving to Phase 3, nothing more.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-15	117
Observed price	2021-09-23	117
Observed price	2021-10-05	102
Observed price	2021-10-13	101
Observed price	2021-10-29	94.4
Observed price	2021-11-02	96.2
Observed price	2021-11-22	80.7
Observed price	2021-11-30	79.9
Observed price	2021-12-04	74.0
Observed price	2021-12-20	81.0
Observed price	2022-01-09	68.6
Observed price	2022-01-13	68.8
Observed price	2022-01-29	61.3
Observed price	2022-02-10	61.9
Observed price	2022-02-22	54.3
Observed price	2022-03-06	54.9
Observed price	2022-03-18	67.0
Observed price	2022-04-03	67.8
Observed price	2022-04-15	61.5
Observed price	2022-04-19	59.0
Observed price	2022-05-09	43.2
Observed price	2022-05-13	52.2
Observed price	2022-06-02	61.0
Observed price	2022-06-14	59.0
Observed price	2022-06-18	68.0
Observed price	2022-06-30	60.8
Observed price	2022-07-16	83.5
Observed price	2022-08-01	76.0
Observed price	2022-08-09	80.1
Observed price	2022-08-17	74.0
Observed price	2022-09-06	62.8
Observed price	2022-09-14	72.2
Observed price	2022-09-26	61.1
Observed price	2022-10-04	65.7
Observed price	2022-10-24	50.4
Observed price	2022-11-09	48.9
Observed price	2022-11-13	60.7
Observed price	2022-11-21	55.5
Observed price	2022-12-07	50.6
Observed price	2022-12-15	48.3
Observed price	2022-12-31	40.6
Observed price	2023-01-08	46.9
Observed price	2023-01-24	52.0
Observed price	2023-02-05	55.5
Observed price	2023-02-21	50.5
Observed price	2023-03-05	49.3
Observed price	2023-03-13	44.7
Observed price	2023-03-25	43.5
Observed price	2023-04-10	45.1
Observed price	2023-04-30	48.5
Observed price	2023-05-04	53.1
Observed price	2023-05-08	56.0
Observed price	2023-05-24	65.9
Observed price	2023-06-05	64.7
Observed price	2023-06-21	57.0
Observed price	2023-07-07	54.9
Observed price	2023-07-11	57.6
Observed price	2023-07-19	57.1
Observed price	2023-08-08	49.6
Observed price	2023-08-20	47.7
Observed price	2023-08-28	50.4
Observed price	2023-09-05	50.3
Observed price	2023-09-25	45.9
Observed price	2023-09-29	45.4
Observed price	2023-10-19	39.8
Observed price	2023-10-27	38.7
Observed price	2023-11-08	54.7
Observed price	2023-11-16	59.2
Observed price	2023-11-20	72.2
Observed price	2023-12-18	65.6
Observed price	2023-12-22	61.5
Observed price	2024-01-19	62.0
Observed price	2024-01-23	66.2
Observed price	2024-01-31	63.0
Observed price	2024-02-16	82.2
Observed price	2024-02-28	86.7
Observed price	2024-03-11	76.2
Observed price	2024-03-19	72.2
Observed price	2024-04-04	65.1
Observed price	2024-04-08	64.1
Observed price	2024-04-28	53.5
Observed price	2024-05-06	57.1
Observed price	2024-05-10	51.2
Observed price	2024-05-30	53.8
Observed price	2024-06-15	62.8
Observed price	2024-06-19	59.1
Observed price	2024-07-05	53.6
Observed price	2024-07-17	59.5
Observed price	2024-08-02	53.6
Observed price	2024-08-10	47.3
Observed price	2024-08-18	49.6
Observed price	2024-09-07	45.1
Observed price	2024-09-19	49.5
Observed price	2024-10-05	45.2
Observed price	2024-10-13	47.5
Observed price	2024-10-25	47.4
Observed price	2024-11-06	50.7
Observed price	2024-11-14	46.9
Observed price	2024-11-30	51.2
Observed price	2024-12-04	50.4
Observed price	2024-12-20	40.4
Observed price	2025-01-05	42.2
Observed price	2025-01-13	38.9
Observed price	2025-01-21	43.5
Observed price	2025-02-10	39.6
Observed price	2025-02-18	52.2
Observed price	2025-03-06	43.3
Observed price	2025-03-10	43.3
Observed price	2025-03-30	35.1
Observed price	2025-04-07	32.4
Observed price	2025-04-11	39.3
Observed price	2025-05-05	34.4
Observed price	2025-05-17	38.9
Observed price	2025-05-29	36.8
Observed price	2025-06-10	42.9
Observed price	2025-06-14	41.4
Observed price	2025-07-04	52.7
Observed price	2025-07-08	54.8
Observed price	2025-07-24	66.1
Observed price	2025-08-13	57.3
Observed price	2025-08-21	52.8
Observed price	2025-08-29	51.8
Observed price	2025-09-14	57.4
Observed price	2025-09-18	60.7
Observed price	2025-10-08	72.8
Observed price	2025-10-20	71.5
Observed price	2025-11-01	62.1
Observed price	2025-11-05	56.5
Observed price	2025-11-21	49.8
Observed price	2025-11-29	52.6
Observed price	2025-12-11	58.1
Observed price	2025-12-23	56.5
Observed price	2025-12-31	53.4
Observed price	2026-01-24	55.2
Observed price	2026-02-05	49.5
Observed price	2026-02-09	48.8
Observed price	2026-03-01	59.1
Observed price	2026-03-09	58.8
Observed price	2026-03-21	46.9
Observed price	2026-03-29	46.7
Observed price	2026-04-18	57.4
Observed price	2026-04-22	55.4
Observed price	2026-04-30	51.2
Observed price	2026-05-16	48.2
Observed price	2026-05-28	56.4
Observed price	2026-06-13	51.4
Observed price	2026-06-29	54.6
Observed price	2026-07-07	60.8
Observed price	2026-07-19	47.3
Observed price	2026-07-27	46.7
Observed price	2026-08-16	54.0
Observed price	2026-08-20	58.1
Observed price	2026-09-09	53.5
Observed price	2026-09-13	52.5
Observed price	2026-09-22	59.0
Observed price	2026-09-25	54.2
Published advisor forecast	2026-09-18	56.6
Published advisor forecast	2026-12-18	60.0
Published advisor forecast	2027-03-18	57.0
Published advisor forecast	2027-06-18	60.9
Published advisor forecast	2027-09-18	58.5
Published advisor forecast	2027-12-18	63.2
Published advisor forecast	2028-03-18	60.0
Published advisor forecast	2028-06-18	63.6
Published advisor forecast	2028-09-18	65.5
Published advisor forecast	2028-12-18	61.6
Published advisor forecast	2029-03-18	65.9
Published advisor forecast	2029-06-18	68.6
Published advisor forecast	2029-09-18	65.1
Published advisor forecast	2029-12-18	69.0
Published advisor forecast	2030-03-18	72.5
Published advisor forecast	2030-06-18	69.6
Published advisor forecast	2030-09-18	73.8
Published advisor forecast	2030-12-18	76.0
Published advisor forecast	2031-03-18	79.8
Published advisor forecast	2031-06-18	77.4
Published advisor forecast	2031-09-18	82.0

2. Scenarios & Signals

Bull case

The bull case activates when biomarker durability becomes outcome credibility. If CTX310's Phase 1b confirms one-year lipid control in symptomatic patients, a large-cap cardiometabolic partner pays a multi-billion upfront, which simultaneously removes the financing overhang, marks the platform at a transacted price and de-risks CTX320, CTX340 and CTX460 by association. Add replicated drug-free remissions from zugo-cel in lupus and CRSP stops being a partnered ex vivo story and becomes a wholly-owned in vivo platform, warranting a multiple on pipeline NPV rather than cash plus hope.

Bear case

The bear case activates if a safety signal appears in any LNP-delivered in vivo program, because the pillars share delivery chemistry and would de-rate together. Layer on a plateau near $400M gross — myeloablative conditioning limits throughput regardless of label breadth — and the 40% share never reaches meaningful contribution. Burn then forces equity issuance around 2029 into a weak tape, expanding share count precisely when option value should concentrate. The equity converges toward net cash, roughly halving from here.

Current crowd narrative

The settled belief is that CRSP is 'cash plus a lottery ticket' — roughly $24 a share of liquidity and a stake the crowd has quietly written off as commercially slow. Sell-side anchors on the 60/40 Vertex split and TTM revenue of $13.4M, treating in vivo editing as free optionality rather than the actual asset. That anchoring is the mispricing.

Alpha-gap assessment

The crowd modestly underestimates these shares, and the blind spot is categorical rather than numerical. Investors price CRSP off the partnered ex vivo asset, where it keeps 40 cents, while the four wholly-owned pillars — in vivo cardiometabolic, allogeneic CAR-T, siRNA and iPSC islets — are where the full economics sit. One-year durable ANGPTL3 knockdown published in NEJM is a platform validation event, not a single-asset datapoint. Against that, a five-percent discount rate and certain keep the gap narrow rather than gaping.

Convergence catalyst

The CTX310 Phase 1b update with the severe-hypertriglyceridemia cohort, guided for H2 2026, is the trigger. Replicating one-year durability in a symptomatic population converts a biomarker curiosity into a registrational asset. The first sign of repricing will be specialist funds bidding the stock through $70 on volume without a print.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.1
Expected volatility regime: high_erratic
Convergence-cycle position: growing_awareness

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
ONE DOSE Replacing A Lifetime OF Lipid P	CTX310's Phase 1a durability is the decisive datum: a single in vivo course cut ANGPTL3 by 79%, triglycerides 48% and LDL 53% at the top dose, sustained through one year, published in NEJM. This is the first credible human proof that a one-time edit substitutes for chronic therapy. Wholly owned economics mean any approval accrues fully to CRSP, not 40%.	Not available	+30.0%
Casgevy's Funnel Finally Converts	The evidence chain is now unambiguous: Vertex booked $76.4M of Casgevy revenue in Q2 2026, up 78% sequentially and 151% year-on-year [1], the highest quarter since 2023 approval. FDA's pediatric extension to age two adds roughly 5,500 eligible patients. CRISPR takes 40% of program profit and cost, so as gross revenue scales past fixed collaboration spend, a chronic P&L drag flips toward contribution.	Not available	+18.0%
A $236bn Runway BUYS THE Answer	Cash and marketable securities stood at $2,364.4M at 30 June 2026 against roughly $110-125M quarterly net burn, implying survival into 2031 without emergency financing [1]. That matters because the binding constraint on option-value equities is not the thesis but the ability to wait for it. Cash of roughly $24 per share also underpins a hard valuation floor beneath the option premium.	Not available	+12.0%
FLAT R&d FOUR NEW INDS	Follow the spending, not the slideware: R&D was $67.2M in Q2 2026 versus $69.9M a year earlier, yet CTX340, CTX460 and CTX611 all entered the clinic on the January guidance schedule. Annual R&D has fallen from $462M (2023) to $265M (2025) while shots on goal rose. That is genuine productivity per dollar, and it stretches runway without visibly narrowing the pipeline.	Not available	+8.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
A FIVE Percent Discount RATE Bites Durat	CRSP is a pure duration asset: essentially all its value sits in cash flows beyond 2030. With the ten-year Treasury at 4.998%, the Fed at 3.75%-4.00% after a unanimous September hike and the median dot implying another, the denominator in any risk-adjusted NPV keeps rising. Every 100bp of term premium removes meaningful present value from 2032-2040 cash flows. This headwind persists while inflation stays near 3.4%.	Not available	-22.0%
Phase 1 Arithmetic IS Unforgiving	The CTX310 durability set is n=15, open-label, with biomarker endpoints; durability is not an outcomes benefit. Historical Phase 1 to approval base rates in cardiometabolic sit near 10%, and CTX320's Lp(a) update has already slipped once on 'evolving landscape' grounds. Over five years the statistically expected outcome is that at least one headline pillar fails, and each failure removes a discrete slice of the roughly $3.1B option premium.	Not available	-18.0%
THE Convert IS Dilution IN A SUIT	Cash rose in H1 2026 because of financing, not operations: $585.4M net from March 2026 convertible senior notes [1]. Reported 'buyback' lines carry negative net buyback yield (-1.29% TTM), meaning net issuance, not capital return. This is the first material leverage layer in the company's history, and conversion or refinancing near 2030-2031 adds share count precisely when pivotal data would otherwise concentrate value per share.	Not available	-14.0%
Vertex Keeps Sixty Cents AND Builds RIVA	CRISPR is the junior partner on its only commercial asset: Vertex leads development, manufacturing and commercialization and takes 60% of profit. Worse, the same partner cleared VX-017, a universal-donor islet therapy that competes directly with CRSP's CTX213 diabetes ambition, while deploying $8.8B on Crinetics. Structural asymmetry in bargaining power caps how much of the gene-editing economics this shareholder ultimately captures.	Not available	-12.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Allogeneic CAR T Cracks Autoimmune Disease	Zugo-cel is wholly owned, and the first refractory SLE patient held drug-free DORIS remission through six months without high-grade CRS or ICANS. If expanded cohorts through 2027-2028 replicate that across lupus, systemic sclerosis and myositis, an off-the-shelf allogeneic product would address a market measured in hundreds of thousands of patients, not thousands, with full economics to CRSP. Probability stays modest because n=4 is anecdote-grade and autologous competitors hold a data lead.	25.0%	+85.0%
BIG Pharma BUYS THE Lipid Franchise	Watch for a cardiometabolic partnership or outright licensing of CTX310/CTX320 to a large-cap with statin-era commercial infrastructure, most plausibly during 2028-2029 once Phase 1b and early Phase 2 durability extend past two years. A multi-billion upfront plus milestones would convert option value into balance-sheet cash, eliminate the dilution overhang, and force analysts to mark the in vivo platform at a transacted price rather than a discounted guess. It stays below 50% because acquirers typically wait for outcomes data, not biomarkers.	30.0%	+70.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
A Liver Toxicity Signal IN VIVO	The single event that would break the platform thesis is a serious hepatotoxicity, off-target editing or immune reaction in an LNP-delivered in vivo program dosed into otherwise healthy-ish cardiometabolic patients. A clinical hold at any point in 2027-2030 would not merely stop one asset; it would re-rate CTX320, CTX340 and CTX460 simultaneously, since all share delivery chemistry. Below 50% because doses to date were tolerated, but n=15 provides thin safety reassurance.	20.0%	-48.0%
Financing AT A Distressed Print	If Casgevy's patient funnel plateaus near a $400M annual gross run-rate while Phase 3 cardiometabolic trials demand $300M-plus annually, management must raise equity around 2029-2030 into a weak tape. An ATM or marketed offering at depressed prices, layered on the March 2026 convertible, would enlarge share count exactly when per-share option value should be concentrating. Probability under 50% because the $2.36bn balance defers the decision, but the arithmetic eventually forces it.	34.0%	-30.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_a8f43c92-6b0f-5e75-9a3d-47a581d28bed__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	+6.0%	59.95	The guided H2 2026 CTX310 Phase 1b update with severe-hypertriglyceridemia cohort data lands, extending the NEJM durability narrative. Q3 Casgevy momentum corroborates. A five-percent ten-year yield and tax-loss selling cap the advance.
2	March 18, 2027	-5.0%	56.96	Post-catalyst drift. Full-year 2026 results reconfirm roughly $500M of annual loss and negative free cash flow, refocusing attention on the convertible overhang while the CTX320 Lp(a) timetable remains unconfirmed.
3	June 18, 2027	+7.0%	60.94	Casgevy quarterly gross clears $120M as pediatric starts convert to infusions. CRSP's collaboration expense line narrows visibly, providing the first tangible evidence that the 40% share economics eventually turn positive.
4	September 18, 2027	-4.0%	58.51	A summer data vacuum coincides with competing siRNA Lp(a) outcomes readouts from larger rivals, compressing the perceived commercial window for CTX320 and reminding investors that CRSP is not first in every lane.
5	December 18, 2027	+8.0%	63.19	Expanded zugo-cel autoimmune cohorts move the evidence beyond anecdote. Durable drug-free remission across lupus and systemic sclerosis patients re-rates the wholly-owned allogeneic CAR-T pillar, where CRSP keeps full economics.
6	March 18, 2028	-5.0%	60.03	Policy stays restrictive longer than the curve assumed, compressing long-duration biotech broadly. Cash drifting below $2.0B revives financing speculation, and the convertible's conversion mechanics enter analyst models explicitly.
7	June 18, 2028	+6.0%	63.63	Regulatory alignment on registrational endpoints for ANGPTL3 editing shortens the perceived path to approval. A defined trial design converts an open-ended research programme into a datable, valuable asset for discounted-cash-flow modellers.
8	September 18, 2028	+3.0%	65.54	Casgevy approaches a $500M annualized gross run-rate as ex-US reimbursement broadens. CRSP's profit share nears neutral contribution, modestly reducing consolidated burn and extending runway assumptions by roughly two quarters.
9	December 18, 2028	-6.0%	61.60	Funding Phase 3 cardiometabolic trials requires capital. An equity programme or second convertible expands share count, diluting per-share option value exactly as the pipeline approaches its most valuable inflection point.
10	March 18, 2029	+7.0%	65.92	A cardiometabolic partnership with a large-cap carrying statin-era commercial infrastructure delivers non-dilutive capital and third-party validation. A transacted price replaces analyst guesswork in valuing the in vivo platform.
11	June 18, 2029	+4.0%	68.55	Phase 2 CTX310 data confirm lipid control persisting past eighteen months in a larger cohort, addressing the central objection that n=15 durability could not generalize beyond dose-escalation participants.
12	September 18, 2029	-5.0%	65.13	Rate-cut expectations disappoint again, prompting rotation out of unprofitable biotech into cash-generative healthcare. CRSP's zero-earnings profile makes it a funding source rather than a destination during the de-risking episode.
13	December 18, 2029	+6.0%	69.03	CTX460 delivers alpha-1 antitrypsin proof-of-concept, demonstrating the in vivo editing platform generalizes beyond lipids. Breadth reduces single-asset dependency and justifies a platform rather than pipeline valuation multiple.
14	March 18, 2030	+5.0%	72.48	Casgevy's contribution turns positively accretive to CRSP's income statement for the first time. The annual loss narrows materially, and the company's burn trajectory finally decouples from its clinical spending.
15	June 18, 2030	-4.0%	69.59	Portfolio attrition arrives as expected: one early-stage programme is discontinued on efficacy or competitive grounds, reminding investors that Phase 1 base rates near ten percent apply here too.
16	September 18, 2030	+6.0%	73.76	CTX213 deviceless islet therapy generates first-in-human signals in type 1 diabetes, opening a fourth economically meaningful pillar despite Vertex's competing universal-donor programme advancing in parallel.
17	December 18, 2030	+3.0%	75.97	Year-end positioning is constructive. Partnership proceeds plus narrowing burn push runway visibility beyond the convertible maturity window, removing the refinancing discount that had persisted since 2028.
18	March 18, 2031	+5.0%	79.77	Anticipation builds ahead of the first registrational cardiometabolic readout. Specialist funds accumulate, and options positioning steepens as the market prices a genuinely binary value-realization event.
19	June 18, 2031	-3.0%	77.38	Pre-data risk reduction. Holders trim into the pivotal readout, a familiar pattern in event-driven biotech, while macro conditions offer no offsetting tailwind to absorb the supply.
20	September 18, 2031	+6.0%	82.02	Clarity on the pivotal ANGPTL3 pathway plus a maturing Casgevy franchise gives CRSP its first credible multi-year revenue visibility beyond the Vertex partnership, supporting a durable valuation re-anchoring.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results - BioSpacebiospace.com

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Universal Investor — THINKER with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.